drug discovery
Jerri Rook is awarded the Alzheimer’s Drug Discovery Foundation’s prestigious Melvin R. Goodes prize
Nov. 2, 2020—Behavioral and systems neuropharmacologist Jerri Rook is recognized by the Alzheimer’s Drug Discovery Foundation with the Goodes Prize to continue her work in Alzheimer’s disease research.
Deep Healing: Two alumni are making waves in drug discovery by plumbing the oceans’ depths for new therapeutic molecules
Sep. 6, 2018—Sirenas, a San Diego-based company founded by Vanderbilt alumni Eduardo Esquenazi, BS'98, and Jake Beverage, BA'98, is applying trailblazing methods toward drug discovery.
Slides can help faculty with Ancora proposal submissions
May. 10, 2018—The Office of the Vice Provost for Research and the Center for Technology Transfer and Commercialization have posted informational slides for faculty preparing pre-proposal submissions in response to the inaugural Ancora request for proposals.
Looking beyond the ‘magic bullet’ approach to drug discovery
May. 1, 2018—Vanderbilt scientists have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.
Nashville Biosciences created to leverage wealth of data
Apr. 5, 2018—Officials with Vanderbilt University Medical Center announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development.
Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer
Mar. 14, 2018—New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.
What’s On My Mind: America’s partnership with its research universities fuels our common future
Feb. 15, 2018—The lasting impact of the historic partnership between the federal government and America's research universities is the topic of this week's column from Chancellor Nicholas S. Zeppos.
Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment
Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
Goal of new tissue-chip research is to assess efficacy of novel epilepsy drugs
Sep. 20, 2017—An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy.
Vanderbilt, Bayer collaborate to develop new therapies against kidney diseases
Sep. 11, 2017—Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
Vanderbilt begins Phase 1 trials of new Alzheimer’s drug
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Vanderbilt, Ono Pharmaceutical extend drug discovery agreement
May. 25, 2017—Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.